Overview

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

Status:
Completed

Trial end date:
2020-05-25

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared to certolizumab pegol in the treatment of subjects with active ankylosing spondylitis (AS).

Phase:

Phase 2

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.

Treatments:

Certolizumab Pegol